The Food and Drug Administration (FDA) last week approved the new non-opioid analgesic suzetrigine (Journavx) to treat moderate to severe acute pain in adults. Suzetrigine is an oral tablet that reduces pain by targeting the NaV1.8 pain-signaling pathway in the peripheral nervous system before the pain signals reach the brain. It is the first drug to be approved in this new class of pain management medicines, according to the FDA. Two randomized, double-blind trials of …
Read More